Citi Maintains Insulet(PODD.US) With Buy Rating, Raises Target Price to $275
Insulet Is Maintained at Buy by Canaccord Genuity
CCORF Maintains Insulet(PODD.US) With Buy Rating, Raises Target Price to $269
Insulet Analyst Ratings
Piper Sandler Maintains Insulet(PODD.US) With Buy Rating, Raises Target Price to $285
Morgan Stanley Maintains Insulet(PODD.US) With Buy Rating, Maintains Target Price $234
Wells Fargo Maintains Insulet(PODD.US) With Buy Rating, Maintains Target Price $245
Strong Growth and Market Leadership Support Buy Rating for Insulet
Jefferies Maintains Insulet(PODD.US) With Buy Rating, Maintains Target Price $260
Insulet Stock Buy Rating: FDA Approval Expands Market Reach for Omnipod 5
A Quick Look at Today's Ratings for Insulet(PODD.US), With a Forecast Between $230 to $264
Buy Rating on Insulet: Early FDA Approval and Market Dominance Signal Strong Growth Potential
TD Cowen Maintains Insulet(PODD.US) With Buy Rating, Maintains Target Price $264
Insulet (PODD) Gets a Buy From TD Cowen
Analysts Offer Insights on Healthcare Companies: Insulet (PODD), Carisma Therapeutics (CARM) and Recursion Pharmaceuticals (RXRX)
The Latest Analyst Ratings For Insulet
Barclays Maintains Equal-Weight on Insulet, Raises Price Target to $220
Barclays Sticks to Their Hold Rating for Insulet (PODD)
Insulet Analyst Ratings
BTIG Adjusts Price Target on Insulet to $250 From $270